News
-
18 January 2022
JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced a strategic investment and exclusive technology licensing agreement with Peijia Medical Limited (HKEX: 9996) in China. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and will commit additional capital and royalty payments based upon various milestone achievements in exchange for exclusive rights to develop and commercialize JenaValve’s innovative Trilogy TAVR systems in the Greater China region to treat patients suffering from either severe symptomatic aortic regurgitation (AR) or severe symptomatic aortic stenosis (AS).
-
14 January 2022
Sonendo, Inc. (“Sonendo”) (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced certain unaudited preliminary revenue results for the fourth quarter and full-year ended December 31, 2021.
-
9 December 2021Sonendo Inc. Reports Third Quarter 2021 Financial Results and Issues Full Year 2021 Revenue Guidance
Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter ended September 30, 2021.
-
7 December 2021
Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or Sequana Medical), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim results from six patients in SAHARA DESERT, the safety and feasibility study of alfapump DSR (Direct Sodium Removal) in heart failure patients with persistent congestion.
-
6 December 2021
Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the completion of patient enrolment in POSEIDON, the North American pivotal study to support regulatory approval of the alfapump system in the U.S. and Canada, for the treatment of recurrent or refractory ascites due to liver cirrhosis.
